SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Kulkarni Shashikant – ‘3/A’ for 7/7/22 re: Neogenomics Inc.

On:  Wednesday, 9/7/22, at 6:41pm ET   ·   For:  7/7/22   ·   As:  Officer   ·   Accession #:  1077183-22-150   ·   File #:  1-35756

Previous ‘3’:  ‘3’ on 7/15/22 for 7/7/22   ·   Latest ‘3’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/07/22  Kulkarni Shashikant               3/A        Officer     1:5K   Neogenomics Inc.                  Neogenomics Inc.

Amendment to Initial Statement of Beneficial Ownership of Securities by an Insider   —   Form 3   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 3/A         Amendment to Initial Statement of Beneficial        HTML      6K 
                Ownership of Securities by an Insider --                         
                wf-form3a_166259047950967.xml/2.6                                




        

This ‘3/A’ Document is an XML Data File that may be rendered in various formats:

  Form 3    –   Plain Text   –  SEC Website  –  EDGAR System  –    XML Data    –  <?xml?> File
 

 
SEC Info rendering:  Amendment to Initial Statement of Beneficial Ownership of Securities by an Insider — wf-form3a_166259047950967.xml/2.6
 
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Kulkarni Shashikant

(Last)(First)(Middle)
9490 NEOGENOMICS WAY

(Street)
FORT MYERSFL33912

(City)(State)(Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
7/7/22
3. Issuer Name and Ticker or Trading Symbol
NEOGENOMICS INC [ NEO ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
XOfficer (give title below) Other (specify below)
President of Lab Operations
5. If Amendment, Date of Original Filed (Month/Day/Year)
7/15/22
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock61,728 (1)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) (2) 4/1/29Common Stock132,744 (3)12.15D
Explanation of Responses:
(1)  This Amended Form 3 reflects an additional 20,576 restricted stock awards granted on April 1, 2022 that were omitted due to administrative error on the original Form 3 filed on July 15, 2022 and the subsequent Form 4 filed on August 3, 2022.
(2)  On April 1, 2022, Dr. Kulkarni was granted 132,744 stock options. These options vest ratably over the first four anniversary dates of the grant date.
(3)  This Amended Form 3 reflects an additional 44,248 stock options granted on April 1, 2022 that were omitted due to administrative error on the original Form 3 filed on July 15, 2022 and the subsequent Form 4 filed on August 3, 2022.
Remarks:
/s/ Ali Olivo, Attorney-in-Fact 9/7/22
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Top
Filing Submission 0001077183-22-000150   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 10:02:44.1am ET